Topics

Cost cuts to the rescue for Teva, so far

08:00 EDT 2 May 2019 | BioPharmaDive

As the Israeli company waits for new products to pick up the slack, aggressive cost-cutting has partially offset sliding sales of Copaxone and generic drugs. 

Original Article: Cost cuts to the rescue for Teva, so far

NEXT ARTICLE

More From BioPortfolio on "Cost cuts to the rescue for Teva, so far"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...